Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats

被引:0
|
作者
Chu, XY [1 ]
Kato, Y [1 ]
Sugiyama, Y [1 ]
机构
[1] UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have reported previously that a canalicular multispecific organic anion transporter (cMOAT) is responsible for the biliary excretion of carboxylate forms of irinotecan, 7-ethyl-10-[4-(1-piperidino)-1 piperidino] carbonyloxy camptothecin (CPT-11), its active metabolite SN-38, and glucuronide conjugate (SN38-Glu) and the lactone form of SN38-Glu in rats. In this paper, the multiplicity of biliary excretion mechanisms for these four anionic compounds was investigated using isolated liver bile canalicular membrane vesicles (CMVs) obtained from Sprague Dawley rats. For the carboxylate form of CPT-11 and the lactone and carboxylate forms of SN38-Glu, ATP-dependent uptake consisted of both high- and low-affinity components in CMVs. Mutual inhibition studies with S-(2,4-dinitrophenyl)glutathione, a representative substrate for cMOAT, and the uptake study using CMVs from Eisai hyperbilirubinemic rats revealed that cMOAT is responsible for the biliary excretion of the low-affinity component of the carboxylate form of CPT-11 and the high-affinity component of both the lactone and carboxylate forms of SN38-Glu, whereas the high-affinity component for CPT-II and the low-affinity component for SN38-Glu, which are expressed in Eisai hyperbilirubinemic rats, are governed by a transporter different from cMOAT. The carboxylate form of SN-38 was found to be transported by cMOAT alone. We conclude that multiple transporters, including cMOAT, are responsible for the biliary excretion of CPT-II and its metabolites (anionic forms), and the contribution of each transporter differs greatly, depending on the substrates.
引用
收藏
页码:1934 / 1938
页数:5
相关论文
共 50 条
  • [21] Irinotecan (CPT-11) in the treatment of mycosis fungoides
    Yokote, T
    Akioka, T
    Oka, S
    Yamano, T
    Hara, S
    Higashi, K
    Enomoto, U
    Kusakabe, H
    Kiyokane, K
    Tsuji, M
    Hanafusa, T
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (05) : 1086 - 1088
  • [22] Irinotecan (CPT-11): Pharmacology and clinical applications
    Masuda, N
    Kudoh, S
    Fukuoka, M
    CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 1996, 24 (01) : 3 - 26
  • [23] Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells
    Yamamoto, W
    Verweij, J
    de Bruijn, P
    de Jonge, MJA
    Takano, H
    Nishiyama, M
    Kurihara, M
    Sparreboom, A
    ANTI-CANCER DRUGS, 2001, 12 (05) : 419 - 432
  • [24] Irinotecan (CPT-11) Chemotherapy Alters Intestinal Microbiota in Tumour Bearing Rats
    Lin, Xiaoxi B.
    Dieleman, Levinus A.
    Ketabi, Ali
    Bibova, Ilona
    Sawyer, Michael B.
    Xue, Hongyu
    Field, Catherine J.
    Baracos, Vickie E.
    Gaenzle, Michael G.
    PLOS ONE, 2012, 7 (07):
  • [25] Effect of Irinotecan (CPT-11) on fatty acid status in rats with colorectal cancer
    Krishnamurthi, Veena
    Pawlowicz, Megan
    Xue, Hongyu
    Baracos, Vickie
    Clandinin, M. Thomas
    Mazurak, Vera C.
    FASEB JOURNAL, 2008, 22
  • [26] Irinotecan (CPT-11) metabolism and disposition in cancer patients
    Sparreboom, A
    de Jonge, MJA
    de Bruijn, P
    Brouwer, E
    Nooter, K
    Loos, WJ
    van Alphen, RJ
    Mathijssen, RHJ
    Stoter, G
    Verweij, J
    CLINICAL CANCER RESEARCH, 1998, 4 (11) : 2747 - 2754
  • [27] The current status of irinotecan (CPT-11) in the United States
    Rothenberg, ML
    CAMPTOTHECINS: FROM DISCOVERY TO THE PATIENT, 1996, 803 : 272 - 281
  • [28] Future directions for clinical research with CPT-11 (irinotecan)
    VonHoff, D
    EUROPEAN JOURNAL OF CANCER, 1996, 32A : S9 - S12
  • [29] Successful salvage treatment with irinotecan (CPT-11) of recurrent malignant lymphoma in an aged patient; and CPT-11 pharmacokinetics
    Yamauchi, T
    Amaya, N
    Yoshio, N
    Yoshida, A
    Tsutani, H
    Ueda, T
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1999, 69 (03) : 165 - 169
  • [30] Molecular predictor of irinotecan (CPT-11) efficacy.
    Rhodes, KE
    Vallböhmer, D
    Zhang, W
    Yang, DY
    Yun, J
    Press, O
    Gordon, M
    Iqbal, S
    Lenz, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 261S - 261S